-
Mashup Score: 3Efficacy and Safety of Tofacitinib in Anti–Melanoma... : JCR: Journal of Clinical Rheumatology - 6 month(s) ago
were treated with tofacitinib and followed up. Clinical and laboratory data of these patients were recorded between January 2019 and June 2022. SPSS was used for all statistical analyses. Results The mean age of patients with MDA5+DM was 45 ± 12.4 years, and the median disease duration was 6.5 months (range, 3–13 months). The mean dosage of glucocorticoids was 34.7 ± 20.9 mg/d at the initiation of tofacitinib therapy. Overall, 47 patients were followed up for a mean duration of 7.8 ± 6.2 months. We found that the clinical symptoms of 28 patients (59.6%) were improved, but 1 patient (2.1%) died because of severe infection. Moreover, complications occurred in 25 patients (53.2%), among whom 19 patients had infections. Older age and C-reactive protein levels close to the upper value in reference range at the initial treatment were found to be the potential risk factors of infection. Furthermore, patients with cutaneous ulcers were found to have a lower risk of infection. Conclusion Tofaci
Source: journals.lww.comCategories: Latest Headlines, RheumatologyTweet
-
Mashup Score: 1Myositis Collection - 7 month(s) ago
Discover the latest myositis research from Rheumatology and Rheumatology Advances in Practice. This collection brings together the latest articles from the Brit
Source: academic.oup.comCategories: Latest Headlines, RheumatologyTweet
-
Mashup Score: 3Myositis Collection - 7 month(s) ago
Discover the latest myositis research from Rheumatology and Rheumatology Advances in Practice. This collection brings together the latest articles from the Brit
Source: academic.oup.comCategories: Latest Headlines, RheumatologyTweet
-
Mashup Score: 8Epidemiology of the idiopathic inflammatory myopathies - Nature Reviews Rheumatology - 7 month(s) ago
In this Review, the authors present epidemiological data relating to the idiopathic inflammatory myopathies and summarize the current understanding of the risk factors associated with these conditions, as well as highlighting areas that require further research.
Source: NatureCategories: Latest Headlines, RheumatologyTweet
-
Mashup Score: 0
of IIM. This review explores the latest advancements of these imaging modalities in IIM. Recent findings Recent advancements in imaging of IIM have seen a shift away from manual and qualitative analysis of the images. Quantitative MRI provides more objective, and potentially more sensitive characterization of fat infiltration and inflammation in muscles. In addition to B-mode ultrasound changes, shearwave elastography offers a new dimension to investigating IIM. PET/CT has the added advantage of including IIM-associated findings such as malignancies. Summary It is evident that MRI, ultrasound and PET/CT have important roles in myositis. Continued technological advancement and a quest for more sophisticated applications help drive innovation; this has especially been so of machine learning/deep learning using artificial intelligence and the developing promise of texture analysis….
Source: journals.lww.comCategories: Latest Headlines, RheumatologyTweet
-
Mashup Score: 7Myositis Collection - 8 month(s) ago
Discover the latest myositis research from Rheumatology and Rheumatology Advances in Practice. This collection brings together the latest articles from the Brit
Source: academic.oup.comCategories: Latest Headlines, RheumatologyTweet
-
Mashup Score: 0Wolters Kluwer Health - 10 month(s) ago
JavaScript Error JavaScript has been disabled on your browser. You must enable it to continue. Here’s how to enable JavaScript in the following browsers: Internet Explorer From the Tools menu, select Options Click the Content tab Select Enable JavaScript Firefox From the Tools…
Source: lww.comCategories: Latest Headlines, RheumatologyTweet
-
Mashup Score: 0
AbstractObjectives. We aimed to evaluate cardiovascular (CV) risk in patients with idiopathic inflammatory myopathies (IIM) compared with healthy controls (HC)
Source: OUP AcademicCategories: Latest Headlines, RheumatologyTweet
-
Mashup Score: 1FDA clears way for CAR T-cell therapy trial in patients with myositis - 12 month(s) ago
The FDA has granted an investigational new drug application for CABA-201, a 4-1BB-containing fully human CD19-CAR T-cell therapy, to be studied in patients with myositis, according to a press release from the manufacturer.
Source: www.healio.comCategories: Latest Headlines, RheumatologyTweet
-
Mashup Score: 0Myositis-specific antibodies a ‘powerful tool’ for diagnosis, management - 12 month(s) ago
DESTIN, Fla. — Understanding which autoantibodies are present in patients with myositis can help with both diagnosis and treatment, according to a presenter at the 2023 Congress of Clinical Rheumatology-East.
Source: www.healio.comCategories: Latest Headlines, RheumatologyTweet
Efficacy and safety of tofacitinib for the treatment of anti-MDA5 antibody-positive #Dermatomyositis https://t.co/D5R6QATW1f #Rheumtwitter #Myositis